Evidence map›Paper›PMID 26538501›Full record

ArticleThe Journal of antimicrobial chemotherapy2016

Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration.

Karl Madaras-Kelly, Makoto Jones, Richard Remington, Christina M Caplinger, Benedikt Huttner, Barbara Jones, Matthew Samore

Registry-linked trialAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05568654 (Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05568654 nacompletednot on this mapstarted 2022, after this paper: background citation

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

TypeinterventionalSponsorThe Cleveland ClinicRan2022 to 2026Enrolled28,580ConditionsCommunity-Acquired Pneumonia, Antimicrobial Stewardship, Point-of-Care TestingArmsRapid Diagnostic Testing, Pharmacist-led de-escalation
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Clinical Impact of the BIOFIRE® FILMARRAY® Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Observational
  2. Article
  3. Article
  4. Antibiotic Use and Presumptive Pathogens in the Veterans Affairs Healthcare System.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Observational
  5. Article
  6. Article
  7. De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  8. Pneumococcal Urinary Antigen Testing in United States Hospitals: A Missed Opportunity for Antimicrobial Stewardship.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Expert Consensus on Metrics to Assess the Impact of Patient-Level Antimicrobial Stewardship Interventions in Acute-Care Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karl Madaras-KellyBoise Veterans Affairs Medical Center, T111, 500 W. Fort Street, Boise, ID 83702, USA College of Pharmacy, Idaho State University, Meridian, ID, USA kmk@pharmacy.isu.edu.
Makoto JonesGeorge E. Whalen Veterans Affairs Medical Center, Salt Lake City, UT, USA Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.
Richard RemingtonBoise Veterans Affairs Medical Center, T111, 500 W. Fort Street, Boise, ID 83702, USA Quantified Inc., Boise, ID, USA.
Christina M CaplingerBoise Veterans Affairs Medical Center, T111, 500 W. Fort Street, Boise, ID 83702, USA College of Pharmacy, Idaho State University, Meridian, ID, USA.
Benedikt HuttnerDivision of Infectious Diseases and Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Barbara JonesGeorge E. Whalen Veterans Affairs Medical Center, Salt Lake City, UT, USA Division of Pulmonology and Critical Care Medicine, University of Utah, Salt Lake City, UT, USA.
Matthew SamoreGeorge E. Whalen Veterans Affairs Medical Center, Salt Lake City, UT, USA Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.

Funding

Antibiotic Spectrum Scoring to Measure Hospital-Level Antibiotic De-escalationR15AI098049 · NIAID · IDAHO STATE UNIVERSITY · PI MADARAS-KELLY, KARL J. · 2012 to 2012
$365k
HSRD VA IK2 HX001165NIAID NIH HHS 1 R15AI098049-01
6 · The paper itself

Abstract

objectivesThe objective of this study was to measure quantitatively antimicrobial de-escalation utilizing electronic medication administration data based on the spectrum of activity for antimicrobial therapy (i.e. spectrum score) to identify variables associated with de-escalation in a nationwide healthcare system.

methodsA retrospective cohort study of patients hospitalized for healthcare-associated pneumonia was conducted in Veterans Affairs Medical Centers (n = 119). Patients hospitalized for healthcare-associated pneumonia on acute-care wards between 5 and 14 days who received antimicrobials for ≥ 3 days during calendar years 2008-11 were evaluated. The spectrum score method was applied at the patient level to measure de-escalation on day 4 of hospitalization. De-escalation was expressed in aggregate and facility-level proportions. Logistic regression was used to assess variables associated with de-escalation. ORs with 95% CIs were reported.

resultsAmong 9319 patients, the de-escalation proportion was 28.3% (95% CI 27.4-29.2), which varied 6-fold across facilities [median (IQR) facility-level de-escalation proportion 29.1% (95% CI 21.7-35.6)]. Variables associated with de-escalation included initial broad-spectrum therapy (OR 1.5, 95% CI 1.4-1.5 for each 10% increase in spectrum), collection of respiratory tract cultures (OR 1.1, 95% CI 1.0-1.2) and care in higher complexity facilities (OR 1.3, 95% CI 1.1-1.6). Respiratory tract cultures were collected from 35.3% (95% CI 32.7-37.7) of patients.

conclusionsDe-escalation of antimicrobial therapy was limited and varied substantially across facilities. De-escalation was associated with respiratory tract culture collection and treatment in a high complexity-level facility.

Indexed as

AgedAged, 80 and overAnti-Bacterial AgentsCross InfectionDrug TherapyFemaleHospitals, VeteransHumansMalePneumonia, BacterialRetrospective StudiesAnti-Bacterial Agents

Identifiers

PMID26538501
PMCPMC4710212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.